You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥-B(1672.HK)高開超6% 中國醫藥全資附屬公司成利托那韋片國內經銷商
格隆匯4月14日丨歌禮制藥高開6.28%報5.08港元,市值55.21億港元。公司昨晚公佈,其全資附屬公司歌禮藥業與中國醫藥保健品有限公司(中國醫藥全資附屬公司)已簽署經銷商協議,成為歌禮藥業利托那韋片在國內的經銷商。據悉,利托那韋片是多種針對病毒蛋白酶的口服抗病毒藥物的藥代動力學增強劑。歌禮制藥擁有目前國內唯一通過生物等效性研究獲批上市的利托那韋口服片,該利托那韋口服片於2021年9月獲國家藥監局批准上市。歌禮制藥已向12個歐洲國家(德國、法國、愛爾蘭、英國、西班牙、葡萄牙、意大利、比利時、波蘭、瑞典、荷蘭和丹麥)和中國香港遞交了利托那韋(100毫克薄膜衣片)上市許可申請。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account